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Summary 
Casdeman's disease is a lymphoproliferative disorder thought to be related to deregulated pro- 
duction oflL-6. We have previously shown that mice lacking the trans-acting factor C/EBP[3, 
a transcriptional regulator of IL-6 and a mediator of IL-6 intracellular signaling,  develop a pa- 
thology nearly identical to multicentric Castleman's  disease,  together with increasingly high 
levels of circulating IL-6. We describe here how the simultaneous inactivation of both IL-6 
and C/EBP]3 genes prevents the development of pathological traits  of Castleman's disease ob- 
served in C/EBPI3-deficient mice. Histological and phenotypic analysis  of lymph nodes and 
spleen of double mutant mice did not show either the lymphoadenopathy and splenomegaly or 
the abnormal expansion of myeloid, B and plasma  cell compartments observed in C/EBP[3-/- 
mice, while B cell development, although delayed, was normal. Our data demonstrate that IL-6 is 
essential  for the development ofmulticentric Castleman's disease in C/EBP[3-/- mice. 
M 
ulticentric Castleman's disease  (CD) is a lymphopro- 
liferative disorder consistently involving multiple pe- 
ripheral lymph nodes and featuring systemic manifestations 
of inflammation and B  cell hyper-reactivity. In contrast to 
localized CD that typically remits after surgical removal of 
the characteristic localized mass, the multicentric form, oc- 
curring in a low percentage of patients, behaves more ag- 
gressively and is frequently fatal,  the main causes  of death 
being sepsis or the development of malignancies, and may 
perhaps represent a different entity (1). The occurrence  of 
the disease  in older age groups, the high frequency of in- 
fectious  complications  and  the  polyclonal  nature  of the 
plasma  cell proliferation, seem to imply a reactive origin of 
the disease underlying some sort ofimmunodeficiency. Al- 
though  the  aethiology of both localized and  multicentric 
CD is unknown, deregulated production of IL-6 has been 
proposed as playing an important role in its pathogenesis. 
The germinal centers from affected lymph nodes produce 
considerable  amounts  of this  cytokine, whose  circulating 
levels directly correlate with clinical manifestations (2). Fur- 
thermore, overexpression of IL-6 in mice generates symp- 
toms closely resembling multicentric CD (3), and treatment 
with IL-6 neutralizing antibodies was recently shown to al- 
leviate systemic manifestations  of a patient with localized 
CD (4). 
IL-6 is a cytokine with multiple functions in immunity, 
hemopoiesis and inflammation (5). It induces terminal dif- 
ferentiation of B  cells to Ig secreting plasma ceils and is a 
potent growth factor for myeloma and plasmacytoma cells, 
where it is thought to play an anti-apoptotic role (6). Both 
IL-6 expression and signaling have been closely linked to 
the transcription factor C/EBPI3 (IL-6DBP, NF-IL6), pro- 
posed as being required for transcriptional induction of the 
IL-6 gene by IL-1/IL-6 (7) as well as being a mediator of 
IL-6 signaling to the nucleus (8). 
We and other groups have recently generated IL-6 and 
C/EBP[3-deficient (-/-)  mice by gene targeting  (9-12). 
While  in  an  unchallenged  state  the  IL-6-/-  mice  were 
healthy and did not show any alteration in the number orB 
lymphocytes and plasma cells,  the C/EBP~-/-  mice de- 
veloped an age-related lymphoproliferative disorder strik- 
ingly similar to that observed in mice overexpressing IL-6 
and nearly identical to that of patients affected by the rare 
and aggressive  form ofmulticentric CD (11). Indeed, these 
mice presented an age-related increase of IL-6 circulating 
levels,  suggesting that the lymphoproliferative disease  may 
be caused by a disruption of the IL-6 regulatory pathway in 
the C/EBPI3-/-  mice, and that a similar disruption might 
also play a role in the pathogenesis of multicentric CD. To 
specifically address these issues we generated mice in which 
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Volume 184  October 1996 1561-1566 Figure 1.  Histological features oflymphnodes (a, c, and e) and spleen (b, d, and f) from C/EBP[~-/- single mutant  (a and b), C/EBP~3 -/-,  IL-6 -/- 
double  nmtant  (c and  d) and wild-type (e and 0  mice.  (a) The paracortical area (PC) near  an hyperplastic  follicle with large germinal centre  (GC)  is 
packed with plasma cells with pseudotumoral  arrangement.  (lnset) Higher magnification of a paracortical plasma cell aggregate. (b) Spleen red pulp  (RP) 
with hyperplastic haemopoietic  tissue in which several megacaryocytes (arrows) are present. These lymph node and spleen histological alterations are ab- 
sent in double mutant  (c and d) and wild-type (e and f) mice. (a-f)  ￿  (#lset) X630. 
both the IL-6 and the C/EBP[3  genes were inactivated, and 
describe here the consequences of this double mutation.  Our 
results indicate that IL-6 is responsible for the development 
of the  nmlticentric  CD-like  disease  in  the  C/EBP[3-/- 
mice. 
Materials  and Methods 
Ge~wration  of IL-6-/-,  C/EBPfl-/-  Double  Mutant  Mice. 
The generation  of IL-6-  and  C/EBP[3-deficient  single  mutant 
mice has  been  recently  described  (11,  12).  Mice  heterozygous 
for  both  mutations  were  obtained  by  intercrossing  IL-6-/- 
1562  IL-6 ￿  C/EBP[3 Double Mutant Mice Figure 2.  Immunohistochemical  features  of lymph nodes front C/EBPI3 
SM (a), wild-type (b), and C/EBPI3-/-, IL-6-/- DM mice (c). (a) Par- 
affin embedded sections of lymph nodes from C/EBP[3 SM (a), wild-type 
(b), and C/EBP[3-/-, IL-6-/- DM (c) mice stained with anti-mouse K 
light chain. Numerous positive plasma cells can be detected in the para- 
cortical area near an hyperplastic follicle in a. No positive cells can be ob- 
served in the same area in b and c. F, follicle  with germinal center (￿ 
and  C/EBP]3-/-  mice.  The  double  heterozygous  mice  were 
then mated to obtain mice homozygous for both mutations. The 
genotypes of the mice obtained from the intercrosses were deter- 
mined by Southern blot as previously described (10,  11). Proce- 
dures involving animals and their care were  conducted in  con- 
formity with national and international laws and policies. 
Histology and lmmunohistochemistry.  Animals  of  different  age 
groups (from 16 to 32 wk of age) were killed by cervical disloca- 
tion. For histologic evaluation, tissues were fixed in  10% neutral 
buffered formalin, embedded in paraffin, sectioned at 4  Ixm and 
stained with hematoxylin-eosin and Giemsa. For immunohisto- 
chemistry, paraffin-embedded sections were  digested with  Pro- 
teinase K  (Dako, Glostrup, Denmark)  in phosphate-buffered sa- 
line, pH  7.6,  for 5  min,  incubated with anti-mouse kappa light 
chain rat monoclonal antibodies (PharMingen, San Diego, CA), 
washed and overlaid with biotinilated rabbit anti-rat Ig (Vector 
Laboratories, Burlingame, CA). Unbound antibody was removed 
by washing, and the slides were incubated with Strep-AB com- 
plex/H1KP (Dako). 
Phenotypic Analysis qf Lymphoid Organs.  Cell  suspensions  were 
single- or  double-stained with  different  monoclonal  antibodies 
(mAbs)  for  flow  cytometric  analysis:  phycoerytrin  (PE)-conju- 
gated anti-CD4  (clone  H  129.19),  FITC-conjugated anti-CD8 
(clone 53-6.7)  and FITC-conjugated anti-CD3 (clone 145-2Cll), 
from Boehringer Mannheim (Mannheim,  Germany). PE-conju- 
gated  anti-CD3  (clone  145-2Cll),  PE-conjugated  anti-B220 
(clone  RA3-6B2),  FITC-conjugated  anti-IgG1  and  anti-IgM 
(clones  G1-6.5  and  P,6-60.2,  respectively),  FITC-conjugated 
anti-CD23  (clone B3B4)  and PE- and FITC-conjugated rat and 
hamster IgG immunoglobulin standard antibody, used as control 
ofimmunofluorescence, from PharMingem 
For staining, 3  ￿  105-10" cells  were incubated on ice with sat- 
urating amounts of antibody, washed in ice-cold PBS, suspended 
in 0.3  ml of ice-cold PBS  and analyzed on  FACScan  |  (Becton 
Dickinson, Mountain View,  CA),  with  at least 1  ￿  104  events 
scored. Dead cells were excluded from the analysis by propidium 
iodide staining. Fluorescence data were analyzed by FACScan  |  or 
Consort 30 programs. 
Results 
Histological  Features  of Lymphoid  Organs from  IL- 6-/-, 
C/EBP~-/-  Double Mutant Mice.  We  previously reported 
that post-mortem examination of C/EBP[3-/-  mice (sin- 
gle  mutant,  SM)  revealed  splenomegaly  and  peripheral 
lymph node  enlargement from  16  wk  of age  (11).  Lymph 
nodes draining areas highly exposed to antigen stimulation 
and/or inflammatory loci showed prominent germinal cen- 
ters  and  a  diffused  plasmacytosis  in  the  paracortical  and 
medullary area  (Fig.  1  A),  with  plasma cells so  numerous 
and crowded that they confer a pseudotumoral appearance 
to  the  nodes involved. This  observation was confirmed by 
immunohistochemical staining with anti-mouse kappa light 
chain (Fig. 2 A), as well as by electron microscopy (data not 
shown).  The  enlarged spleens showed white  and  red pulp 
hyperplasia  due  to  the  expansion  of both  lymphoid  and 
myeloid compartments  (Fig.  1  B).  The  diffuse plasmacyto- 
sis in lymph nodes  and spleen and the splenic hyperplastic 
hemopoietic tissue were  observed in all but one  of the 20 
C/EBP[3  SM mice studied from  16  through 32 wk of age. 
In contrast, DM mice failed to show any major alterations 
1563  Screpanti et al.  Brief Definitive Report =)  r 
4000 
1000  l 
:a  ~,=o 
~o  "6 
_-  ] 
1  ,  ,  ,  ,  c 
16  Z~  Z7  3'Z  Zl  2;'  12 
b)  d) 
ioooo  6c~c 
T 
looo-  ; 
w  w 
m  m 
16  21  2;"  32  E1  27  32 
￿9  Age  (weeks)  I= 
Figure 3.  Pheno~pic analysis ofsp]emc (a and b) and lymph node (r and 
d)  cells.  IL-6-/-,  C/EBH3-/-  double  Juutant  mice  (z~);  IL-6-/-- 
mice (O); wild-type mice (~); C/EBP[3-/- mice ([]). (a) Total splenic 
lymphocytes recovered at different ages, The results are expressed in loga- 
rithmic scale, as percentage of increase of DM or SM total splenic lym- 
phocytes with respect to the total yield of wild-type splenic lymphocytes 
for each specific age considered as 100%. (b) Percentage of B22()  + lym- 
phocytes recovered at each age from the spleens of the different  mutant or 
wild-type mice. The results are expressed iIl logarithmic scale. (c) Total 
lymph node lymphocytes recovered at different ages. The results are ex- 
pressed in linear scale, as percent variation  with respect to wild-type mice 
considered as  100%. (d)  Percentage o( B220  + lymphocytes recovered 
from lymph nodes of different mutant or wild-type mice at different  ages. 
l~.esults represent average values +  SD obtained from three to five mice 
per each age and genotype group. 
in the  lymphoid organs.  Moreover,  the  histological alter- 
ations observed in the lymph nodes and spleens of the C/ 
EBP[3  SM mice were not detected in either the  IL-6, C/ 
EBP[3 double nmtant (DM)  (Fig. 1,  C and D  and Fig. 2  C) 
or the  IL-6 SM mice  (not shown).  In these  animals, as in 
the wild-type mice, well developed germinal centers were 
present  in  the  cortical  areas  of lymph  nodes  and  in  the 
white  pulp  of spleen  (Fig.  1,  C-F).  Mature  plasma  cells 
were  observed in lymph node medullary cords  (Fig.  1,  C 
and E)  as well as in the intestinal mucosa and the peribron- 
chial region of the lung (not shown). Remarkably, the 1)M 
mice did not show any sign of the dramatic plasmacytosis 
detected in the lymph nodes of the C/EBP[3 SM mice as 
shown by the histological analysis (Fig.  1, compare A  with 
C),  and  failed  to  stain  with  anti-K light  chain antibodies 
(Fig. 2, compare A  with C). DM mice did not show either 
any spleen hyperplasia or expansion of lymphoid and mye- 
loid compartments (Fig.  1,  B and D).  These data  indicate 
that IL-6 plays an essential role in the development of the 
lymphoproliferative and  myeloproliferative disease  devel- 
oped by the C/EBP[3 SM mice. 
Inactiuation of the  IL-6  Gene Reverses the Abnormal  B  and 
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Figure  4.  Thymus  development in  IL-6-/-, C/EBP[3-/-  double 
mutant mice. (A) Total thymocytes recovered at different ages. The re- 
suits are expressed as percent variation of I)M (A) or IL-6 SM (O) total 
thymocytes with respect to the total yield of thymocytes obtained from 
wild-type or C/EBP~ SM mice, that are coincident (O) E)r each specific 
age considered  as 100%. P, esults represent average values + SI) obtained 
fi'om at least three mice per each age and genotype group. (/3) Two-color 
analysis of C1)4 vs CI)8 expression of thymocytcs recovered from wild- 
type (W"/), IL-6 -/-  SM or I)M mice. The results are representative  of 
three similar  experiments. 
shown,  total  cell  recovery  from  both  the  spleen and  the 
lymph nodes of C/EBP[3 SM mice strongly increased from 
21  wk of age onwards, matching the  enlargement of both 
organs  observed  in  post-mortem  examination (Fig.  3,  A 
and C). This increase involved a dramatic expansion of the 
B  cell  compartment,  as  shown  by  the  abnormally  high 
number of cells expressing surface B220 antigen (Fig. 3,  B 
and D).  In contrast,  total cell recovery never increased in 
either spleen or  lymph nodes from the DM mice (Fig. 3, A 
and C). Moreover, the flow cytometric analysis of lympho- 
cyte subsets in spleen and lymph nodes clearly showed that 
the  number of B220  expressing cells  did  not  increase  in 
comparison to  the wild-type mice (Fig. 3,  B and D).  As a 
control, total cell yield and percentage of B220 + lympho- 
cytes  were  analyzed in IL-6  SM  mice,  and proved  to  be 
normal from 27 wk onwards (see below) (Fig. 3, A-D).  In 
most of the  I)M mice,  the  expression of lgM,  lgG1, and 
CD23 by lymphocytes from spleen and lymph nodes were 
also  analyzed and  always came  within  the  normal ranges 
(not shown). 
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C/EBP~8-/- Double Mutant Mice.  It has been previously 
shown that young (6-12-wk-old) IL-6-/-  mice present a 
reduction in the total number ofthymocytes and peripheral 
T  cells, but maintain a normal subset distribution for what 
concern the expression of CD4, CD8, and T  cell receptor 
repertoire  (9).  We  have  found  that  also  older  IL-6-/- 
mice (from 16 wk of age) have a decreased number ofthy- 
mocytes (Fig. 4 A). Although we never observed any alter- 
ation  with  respect to  normal  mice  in  phenotype  or  cell 
number in the thymus of the C/EBP[3 SM mice (11),  the 
DM mice showed, at all ages analyzed, a decrease in total 
thymocyte number comparable to that found in the IL-6 
SM mice: this decrease was slightly higher at younger ages 
in both kinds  of mice  (Fig.  4 A).  The subset  distribution 
did not present any significant alteration in either SM  or 
DM mice with respect to the wild-type controls (Fig. 4 B). 
These  data  suggest  that  while  IL-6  is  involved  in  thy- 
mocyte proliferation mainly at young ages,  its  absence  is 
less critical when involution of the  thymus has  started; it 
would also appear that C/EBP[3 does not play an important 
role  in  thymocyte proliferation and/or  differentiation, at 
least in the age groups studied. 
The total mononucleated cell number also  significantly 
decreased in the spleen of IL-6 SM mice at 16 and 21  wk 
of age, but became normal by the 27th wk (Fig. 3 A). This 
decrease involved both CD3 §  T  cells and B220  + B  lym- 
phocytes (not shown and Fig.  3 B). Interestingly, not only 
was the decrease in total cell yield and percentage of  B220 + 
lymphocytes also  detected in the spleens of the DM mice 
(Fig.  3), but it was significantly more pronounced than in 
the IL-6 SM mice, suggesting that IL-6 and C/EBP[3 act 
synergically in splenic lymphocyte development. 
Discussion 
IL-6 is a potent growth factor for myeloma and plasma- 
cytoma  cells  (13),  being required for in  vitro  growth  of 
both primary cell explants and established cell lines.  In par- 
allel with its growth promoting activity, IL-6 is thought to 
exert an anti-apoptotic effect on myeloma cells in vitro and 
possibly in vivo, thus playing an important role in the ex- 
pansion of the tumor population  (6).  On the  other hand, 
IL-6 overproduction has also been linked to non-malignant 
lymphoproliferative disorders such as CD  (2), where again 
it may inhibit the naturally occurring apoptotic suppression 
of B  and plasma  cell populations which  have  undergone 
expansion after antigenic stimuli. We have previously shown 
that mice lacking the transcription factor C/EBP[3 develop 
an  age-related lymphoproliferative and  myeloproliferative 
disorder reminiscent of multicentric CD and possibly linked 
to IL-6 overproduction (11). Here we show that this disor- 
der  can  be  completely blocked by inactivating  the  IL-6 
gene, indicating that indeed deregulation of IL-6 produc- 
tion may represent one of the triggering events. It is tempt- 
ing to speculate that interference with the normal activity 
of C/EBP[3 and the consequent IL-6 deregulation, might 
be among the causes  of CD, a disease whose aethiology is 
still  unknown.  In  this  light,  the  localized or multicentric 
CD forms might arise from inactivation of C/EBP[5 occur- 
ring either in very early myeloid/B lymphoid precursors, 
or in B  cells at later differentiation stages.  Moreover, pro- 
viding a model of multicentric CD development in which 
the abnormal lymphoproliferation can be prevented by IL-6 
gene inactivation supports the hypothesis that IL-6 plays  a 
critical role in multicentric CD pathogenesis. 
Interestingly, a deletion of human chromosome 20q in- 
volving the region in which the  C/EBP[3 gene maps has 
been reported in several cases of myeloproliferative disor- 
ders and myelodisplastic syndromes (14),  and in  16 out of 
68 patients (24%) affected by myeloid leukemia (15).  It has 
also been shown that such a deletion in myelodysplasia can 
arise in a multipotent precursor of both myeloid and B cells, 
suggesting that this mutation can cause a  disease  arising 
in a cell with both myeloid and lymphoid potential (16). 
These reports together with  our observation of abnormal 
proliferation in both myeloid and B  cell compartments 
in  C/EBP[3-/-  mice,  suggest  that  inactivation  of the 
C/EBP[3 gene could represent a link between myelo- and 
lympho-proliferative disorders.  If this  is  indeed  the  case, 
blockage of IL-6 produc6on could help interfere with myelo- 
and/or lympho-proliferative disorders involving C/EBP[3 
gene inactivation. 
Although IL-6 is an important B  cell growth factor and 
C/EBP[3 has been suggested to play a role in B cell devel- 
opment, our data also show that both IL-6 SM and IL-6, 
C/EBP[3 DM mice have well-developed germinal centers 
in both lymph nodes and spleen, and mature plasma cells in 
several tissues,  thus indicating that neither gene product is 
essential for B cell proliferation and final maturation. How- 
ever, it is interesting to note that younger IL-6 SM mice 
showed a significant reduction in total cellularity  and B220  + 
lymphocytes in the spleen up to 27 wk of age, suggesting 
that IL-6 does play a role in regulating B lymphocyte pro- 
liferation  at  young  ages,  although  it  can  be  functionally 
compensated for by other cytokines thereafter. Moreover, the 
B cell population dropped even further when the C/EBP[3 
gene  was  also  inactivated,  suggesting  that  the  two  genes 
play partly independent roles, C/EBP[3 probably being in- 
volved in the signaling of B  cell growth factors other than 
IL-6. One of such factors may be IL-7, since it was recently 
shown that bone marrow stromal cells from C/EBPI3 SM 
mice  have  a  reduced potential  for B  cell  differentiation, 
which could be related to a defect in responsiveness to IL-7 
(Chen, X., W. Liu, C. Ambrosino, M.R. Ruocco, V. Poli, 
L. Romani, I. Quinto, S. Venuta, and G. Scala, manuscript 
submitted for publication). 
We  have previously suggested that  the  deregulation of 
IL-6 expression in the C/EBP[3-/-  mice may either be a 
consequence  of defects  in  their  immune  system,  which 
cause a chronic preferential expansion of CD4 + T  helper 
type 2 cell population, producing IL-6 among other cyto- 
kines, or it may be due to C/EBP[3 playing a direct role in 
regulating IL-6 gene transcription, or both (11).  Although 
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the IL-6 gene  (7), our data imply that it may instead act as 
an inhibitor. Indeed, Kishimoto and colleagues have shown 
that peritoneal macrophages from C/EBH3  (NF-IL6)-defi- 
cient  mice  constantly  produce  IL-6  (12),  suggesting  that 
the  IL-6 gene may be chronically active in the absence of 
this  transcription  factor,  at least in  certain conditions and 
cell types. We have also recently observed that thymic stro- 
mal  cells derived from  the  C/EBH3-/-  mice  showed  a 
significant enhancement  of IL-6 induction  in  response  to 
IL-6  treatment  (Screpanti,  I.,  and  M.  Maroder,  unpub- 
lished  observation),  again  indicating deregulation  of IL-6 
gene  transcription and possibly increased sensitivity to  the 
IL-6-induced signaling pathway. Only more detailed stud- 
ies performed on cell lines of different kinds derived from 
the  mutant  mice  will  atlow  the  precise  definition of the 
molecular basis for IL-6 deregulation in the C/EBP[3-/- 
mice. 
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